Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette-Guérin vector candidate vaccine for human immunodeficiency virus type 1 in small animals.
about
Progress in HIV vaccine research.Recombinant Mycobacterium bovis BCG as an HIV vaccine vector.Detection of natural infection with Mycobacterium intracellulare in healthy wild-caught Chacma baboons (Papio ursinus) by ESAT-6 and CFP-10 IFN-gamma ELISPOT tests following a tuberculosis outbreakAIDS vaccine development: let a thousand flowers bloom.Recombinant pro-apoptotic Mycobacterium tuberculosis generates CD8+ T cell responses against human immunodeficiency virus type 1 Env and M. tuberculosis in neonatal mice.Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.Mycobacterial codon optimization enhances antigen expression and virus-specific immune responses in recombinant Mycobacterium bovis bacille Calmette-Guérin expressing human immunodeficiency virus type 1 Gag.Humoral and cellular immune responses in mice immunized with recombinant Mycobacterium bovis Bacillus Calmette-Guérin producing a pertussis toxin-tetanus toxin hybrid protein.Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guérin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity.Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C.Generation of CD8+ T-cell responses by a recombinant nonpathogenic Mycobacterium smegmatis vaccine vector expressing human immunodeficiency virus type 1 Env.Pre-clinical development of BCG.HIVA(CAT), an antibiotic-free selection strain, for HIV-TB pediatric vaccine vectored by lysine auxotroph of BCG.Efficiency of recombinant bacille Calmette-Guérin in inducing humoral and cell mediated immunities against human immunodeficiency virus type 1 third variable domain in immunized mice.Sequential immunization with V3 peptides from primary human immunodeficiency virus type 1 produces cross-neutralizing antibodies against primary isolates with a matching narrow-neutralization sequence motif.Anti-V3 humanized antibody KD-247 effectively suppresses ex vivo generation of human immunodeficiency virus type 1 and affords sterile protection of monkeys against a heterologous simian/human immunodeficiency virus infection.Newborn mice vaccination with BCG.HIVA²²² + MVA.HIVA enhances HIV-1-specific immune responses: influence of age and immunization routesGeneration of mucosal anti-human immunodeficiency virus type 1 T-cell responses by recombinant Mycobacterium smegmatisEngineering new mycobacterial vaccine design for HIV-TB pediatric vaccine vectored by lysine auxotroph of BCGTh1 cytokine-secreting recombinant Mycobacterium bovis bacillus Calmette-Guérin and prospective use in immunotherapy of bladder cancer.Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector.Mycobacterium bovis Bacille Calmette-Guérin as a Vaccine Vector for Global Infectious Disease ControlProgress towards an HIV vaccine based on recombinant bacillus Calmette-Guérin: failures and challenges.A model of a gp120 V3 peptide in complex with an HIV-neutralizing antibody based on NMR and mutant cycle-derived constraints.Nucleotide sequence variation of human T-lymphotropic virus type II in Vietnam.Dependence of Mycobacterium bovis BCG on anaerobic nitrate reductase for persistence is tissue specific.Oral immunization with recombinant Mycobacterium bovis BCG simian immunodeficiency virus nef induces local and systemic cytotoxic T-lymphocyte responses in mice.Preclinical development of BCG.HIVA2auxo.int, harboring an integrative expression vector, for a HIV-TB Pediatric vaccine. Enhancement of stability and specific HIV-1 T-cell immunity.HIV/AIDS Vaccine Development: Challenges, Progress and Future Directions.Father-to-mother-to-infant transmission of HIV-1: clonally transmitted isolate of infant mutates more rapidly than that of the mother and rapidly loses reactivity with neutralizing antibody.Development of a Live Recombinant BCG Expressing Human Immunodeficiency Virus Type 1 (HIV-1) Gag Using a pMyong2 Vector System: Potential Use As a Novel HIV-1 Vaccine.
P2860
Q30331429-AE1D6CE4-11DF-4E66-BC0A-192F2B0D07A4Q30387447-F59651E4-2FE1-48F4-B373-073F1CB2F2D1Q33318591-98239F90-1195-4255-92AE-2A3931AD46A1Q33534217-86E8DAE2-C42F-48D9-AA94-6F32CF5FB43FQ33584559-49EEF51B-10C6-4331-8062-8E24AAC42A46Q33717525-A8F39885-D639-433F-99BA-A16EF4F7600DQ33883995-21761CF5-9DA8-419D-8C80-456AF23A5FE9Q34002019-D3F2836C-2E3E-41D1-8665-C9726A50D98DQ34045678-31415721-197E-46E5-9F5E-B2A894ED0BA5Q34348269-E7D29735-3AB0-493D-B4FF-FEE0403D25F4Q34353428-DC2B2342-CE40-4FAF-8FE9-A92B127E1869Q34395523-79BC7BE7-65BA-46E3-924E-737D5C7DA49BQ34474562-2707B085-839C-46D9-82D2-651FC00DE72CQ34648342-30069169-B4D8-4926-94F3-1FCDB79C4DAAQ34648429-D4BC45B8-0490-461F-89A5-D7473B739E12Q34983688-49E55FED-4FC3-4827-9810-59788AEE69A0Q35160697-88BEEEF2-1E41-4DE6-A001-948ACBA55245Q35184235-C2D6DECD-40E5-4890-9E71-668C50955FF7Q35215350-BB5365ED-7000-484B-9441-77072E0A4659Q35881081-37BF735B-94CF-48A8-BC36-D57BCACFB3C7Q35909944-36B3BED0-D2B1-4D34-BA76-FF69B7A4174FQ36690291-B23FF5BC-2D6D-4CFC-A041-C97531E6E718Q38315995-3063E396-D92D-4A43-8F10-8444D4D70DC0Q39456003-2F2E3309-F870-457C-9140-F89353179BF0Q39653537-68F9D3EA-ACE6-48F2-B466-9955913B72F2Q39878736-2FCD18E1-F30E-4B09-839D-60D2636ECD41Q40234787-1AE1B534-A8FB-4FF5-A9D3-39992EA48919Q40927003-2CF97E01-4570-4697-B8CC-234A00B1B5A0Q48055865-52EC144F-5B80-4D12-8552-FBDE2DC283D7Q52595182-C712DAE4-BC62-495E-B8F0-768ED384FCC0
P2860
Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette-Guérin vector candidate vaccine for human immunodeficiency virus type 1 in small animals.
description
1995 nî lūn-bûn
@nan
1995 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Protective immune responses in ...... virus type 1 in small animals.
@ast
Protective immune responses in ...... virus type 1 in small animals.
@en
type
label
Protective immune responses in ...... virus type 1 in small animals.
@ast
Protective immune responses in ...... virus type 1 in small animals.
@en
prefLabel
Protective immune responses in ...... virus type 1 in small animals.
@ast
Protective immune responses in ...... virus type 1 in small animals.
@en
P2093
P2860
P356
P1476
Protective immune responses in ...... virus type 1 in small animals.
@en
P2093
Fukushima Y
Kitamura K
Nakasone T
P2860
P304
10693-10697
P356
10.1073/PNAS.92.23.10693
P407
P577
1995-11-01T00:00:00Z